Biofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Revenues between $17.0 Million and $17.5 Million, Representing Approximately 35% Year-Over-Year Growth

Core Insights - Biofrontera Inc. announced preliminary unaudited revenue results for Q4 2025, expecting revenues between $17.0 million and $17.5 million, marking the highest quarterly revenue in the company's history [1][8] - For the full year 2025, revenues are projected to be between $41.5 million and $42.0 million, indicating a year-over-year growth of approximately 11% to 13% [2][8] - The strong performance in Q4 was attributed to effective sales execution of Ameluz® PDT and a pricing adjustment made in December [3][8] Financial Performance - Q4 2025 revenues are expected to show a year-over-year growth of 35% to 39% driven by the sales of Ameluz® [8] - The company anticipates reporting complete financial results for Q4 and the full year 2025 in March 2026 [2][4] Strategic Developments - The recent transaction with Biofrontera AG is expected to significantly improve the company's gross margin profile and strengthen its financial foundation [4] - The CEO expressed confidence in the company's innovative products and operational excellence, which are expected to drive sustainable growth in 2026 [3][4] Upcoming Events - Biofrontera management is scheduled to present at the Lytham Partners Healthcare Investor Summit on January 15, 2026 [5]